Literature DB >> 10623431

Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis.

A Boe1, M Baiocchi, M Carbonatto, R Papoian, O Serlupi-Crescenzi.   

Abstract

In order to assess the potential role of IL-6 in rheumatoid arthritis (RA), we have compared IL-6 deficient (IL-6 ko) mice and their wild-type (wt) counterpart for the capacity to develop methylated bovine serum albumin (mBSA)-induced arthritis. Our data show that IL-6 ko mice are not susceptible to antigen-induced arthritis (AIA). In fact, IL-6 ko mice treated by a standard protocol of immunization with mBSA did not develop joint swelling following intra-articular mBSA injection, nor revealed the characteristic joint lesions by histological examination. Conversely, wt mice treated according to the same protocol developed arthritis about 9 days after intra-articular injection, as detected by knee joint swelling and histological confirmation. We observed that the proliferative response of splenocytes to mBSA was impaired in ko mice following arthritis induction, as compared to the strong response observed in wt mice. Furthermore, anti-mBSA IgG levels were lower in ko mice as compared to wt mice. Finally, we show that sensitivity to AIA can be reconstituted in ko mice by subcutaneous injections of recombinant human IL-6 (rhIL-6). In addition, co-administration of IL-6 with mBSA by intra-articular injection into the joint was only partially effective in conferring sensitivity to AIA, suggesting the importance of a systemic effct for IL-6, but also that an additional role for this cytokine can be envisaged in the local inflammatory reaction during establishment of AIA. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10623431     DOI: 10.1006/cyto.1999.0502

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  29 in total

1.  Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.

Authors:  E Choy
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Methylation and microRNA-mediated epigenetic regulation of SOCS3.

Authors:  Chandra S Boosani; Devendra K Agrawal
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

Review 3.  Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis.

Authors:  Gianfranco Ferraccioli; Luisa Bracci-Laudiero; Stefano Alivernini; Elisa Gremese; Barbara Tolusso; Fabrizio De Benedetti
Journal:  Mol Med       Date:  2010-08-02       Impact factor: 6.354

4.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-alpha-stimulated gene-6) in murine models of experimental arthritis.

Authors:  T Bárdos; R V Kamath; K Mikecz; T T Glant
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.

Authors:  Srinivasan Srirangan; Ernest H Choy
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

Review 7.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

8.  Enhancement of anti-inflammatory tendency by SB203580, p38alpha specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A.

Authors:  Seon Kyu Han; Su Jin Jeon; Keiji Miyazawa; Seh Yoon Yi; Young Sook Yoo
Journal:  Rheumatol Int       Date:  2006-03-11       Impact factor: 2.631

9.  Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis.

Authors:  Michael K Boettger; Johannes Leuchtweis; Diana Kümmel; Mieczyslaw Gajda; Rolf Bräuer; Hans-Georg Schaible
Journal:  Arthritis Res Ther       Date:  2010-07-13       Impact factor: 5.156

10.  Observations of Forsythia koreana methanol extract on mast cell-mediated allergic reactions in experimental models.

Authors:  In-Young Choi; Phil-Dong Moon; Hyun-Na Koo; Noh-Yil Myung; Su-Jin Kim; Ji-Hyun Lee; Se-Hee Han; Goo Moon; Sung-Yum Seo; Hyun-Jea Sung; Rae-Kil Park; Hyun-Ja Jeong; Jae-Young Um; Hyung-Min Kim; Seung-Heon Hong
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-08-25       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.